E-Mail
A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls. The final results were published online on Jan. 21 in
Cancer Discovery, a journal of the American Association for Cancer Research.
Advances in technology have made it possible for scientists and physicians to use information about the genetic makeup of a cancerous tumor to inform cancer treatment, but genetic heterogeneity the genetic variation between cancers in different patients and even between tumors within the same patient can make it difficult to determine the most effective targeting strategy for treating individual patients.